Rigenera

What Rigenera does

Rigenera HBW (legal entity: Human Brain Wave S.r.l.) is an Italian medical technology company founded in 2012 in Turin by Dr. Antonio Graziano and Dr. Riccardo D'Aquino, specializing in patented autologous micrografting devices for regenerative medicine. The core Rigenera® technology platform mechanically disaggregates patient tissue biopsies into 80 μm micrografts containing progenitor cells, exosomes, and extracellular matrix, achieving 90% biological component viability in a 30-minute point-of-care procedure performed under local anesthesia. The platform comprises the disposable sterile Rigeneracons device, the Transmisor, and an electromechanical rotator operating at a calibrated 80 rpm.

The company markets four clinical vertical sub-brands: Woundigen (wound healing and plastic surgery), StrongBone SB (dental and oral & maxillofacial surgery), Regenera Activa AMT (aesthetic medicine for hair loss, scarring, and skin rejuvenation), and Mytocel MSK (pain management and sports medicine). Each vertical uses variant Rigeneracons devices (DS, RS, Derma, and wound-healing variants) and supporting accessories (Sicurdrill, Sicurlid, Sicurstick, Adipecons, Adac, Spray Tip, N4SA Machine). Rigenera HBW holds 11 patents, CE Mark as a Class IIa device, US-FDA listing, MDR compliance, and 30+ national medical certifications, supported by 80+ scientific publications.

Revenue is generated through two streams: hardware sales of single-use disposable medical devices and capital equipment to healthcare providers, and technology licensing for global distribution. Distribution is hybrid — HBW directly manages wound healing, plastic surgery, and dental/OMF lines, while partner Regenera Activa manages worldwide distribution of dermatology, aesthetic medicine, and pain management lines. The technology is currently used by 6,000+ partner physicians across 60+ countries, with 500,000+ cumulative treatments recorded. The company is privately held, founder-funded, and operates from its Candiolo (Turin) headquarters with regional offices in Hong Kong, Brazil, and the United States.

Name

Rigenera

Legal name

HBW, Human Brain Wave S.r.l.

Website

https://rigenerahbw.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Rigenera HBW is an Italian medical technology company that develops and distributes the patented Rigenera® autologous micrografting platform — disposable devices that mechanically disaggregate patient tissue into micrografts for regenerative medicine. It serves physicians across wound healing, dental, aesthetic, and pain management verticals in 60+ countries.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industry

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

Keywords

• Autologous micrografting technology
• Regenerative medicine devices
• Wound healing solutions
• Dental bone regeneration
• Aesthetic medicine devices

Headquarters

HQ city

Torino

HQ country

Italy

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure, Others

Revenue model

1. Medical Device Sales (Rigeneracons and Accessories): Sale of disposable sterile medical devices (Rigeneracons, Adipecons, Sicurdrill, Sicurstick, Sicurlid, Spray Tip) and equipment (N4SA Machine) used in the Rigenera® micrografting procedure. Products are sold to healthcare providers including surgeons and physicians for use in regenerative medicine treatments.
2. Technology Licensing: Patented Rigenera® technology is licensed for use across 60+ countries worldwide through direct HBW distribution and partnership with Regenera Activa for specific product lines.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Rigenera® is a patented autologous micrografting medical device platform that mechanically disaggregates a small patient tissue biopsy into 80 μm micrografts (containing Progenitor Cells, Exosomes, and Extra-Cellular Matrix) for autologous administration to damaged tissue. The system comprises the disposable Rigeneracons device, Transmisor, and Electromechanical Rotator, and is commercialized across four clinical application lines: Wound Healing (Woundigen), Dental & Oral & Maxillofacial Surgery (StrongBone SB), Aesthetic Medicine (Regenera Activa AMT), and Pain Management & Sport Medicine (Mytocel MSK).

Product overview

Rigenera HBW is a science-driven medical technology company founded in 2012 by Dr. Antonio Graziano and Dr. Riccardo D'Aquino, specializing in advanced regenerative medicine. The core offering is the patented Rigenera Technology Platform, a one-of-a-kind Made in Italy autologous micrografting system that mechanically disaggregates patient tissue into micrografts for tissue regeneration. The platform consists of the Rigeneracons disposable medical device, Transmisor, and Electromechanical Rotator. Rigenera HBW offers four clinical application sub-brands: Woundigen (wound healing), StrongBone SB (dental and oral & maxillofacial surgery), Regenera Activa AMT (aesthetic medicine), and Mytocel MSK (pain management and sport medicine). Supporting components include SICURDRILL, SICURSTICK, SICURLID, ADACONS, ADIPECONS, SPRAY TIP, and the N4SA Machine. The technology achieves 80 micrometer micrografts with 90% biological components viability, is registered in 60+ countries, and has supported over 500,000 treatments performed by 6,000+ partner physicians.

Differentiator

Problem solved

Functional benefit

Brands

• Woundigen: Wound healing product line including Rigeneracons 0S, Adipecons, Sicurdrill, Sicurstick, Sicurlid, and Spray Tip for treating acute and chronic wounds
• StrongBone SB
• Regenera Activa AMT
• Mytocel MSK

Products and services

• Woundigen Wound healing clinical application line of Rigenera® products designed to treat acute and chronic wounds including vascular/venous or diabetic ulcers, burns, surgical dehiscences, oncological and post-surgical wounds, post-traumatic wounds, and non-healing wounds through autologous micrografting. Targeted at wound care specialists, plastic surgeons, and reconstructive surgeons.
• StrongBone SB Dental and Oral & Maxillofacial Surgery clinical application line for bone regeneration, periodontal regeneration, sinus lift augmentation, socket preservation, maxillary osteonecrosis treatment, large defect management, and GBR/GTR procedures. Targeted at dental surgeons and oral-maxillofacial surgeons.
• Regenera Activa AMT Aesthetic medicine clinical application line for androgenetic alopecia treatment, scar treatment (surgical, traumatological, acneic), hair thickening, skin rejuvenation, and stretch marks using autologous micrografting. Targeted at dermatologists and aesthetic medicine practitioners.
• Mytocel MSK Pain management and sport medicine clinical application line for musculoskeletal repair, treating chondropathy, sports injuries, and joint pain using autologous micrografting. Targeted at orthopedic surgeons and sports medicine physicians.
• Rigenera® Technology Platform Core patented autologous micrografting technology platform consisting of Rigeneracons (disposable Class IIa CE-marked medical device), Transmisor, and Electromechanical Rotator. Produces 80 μm micrografts with 90% biological components viability from patient tissue for tissue regeneration across wound healing, dental, aesthetic medicine, and musculoskeletal applications.

Quantifiable outcome

• 500,000+ successful treatments performed worldwide
• +4 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered minor, strategic and core.

• CEIPIEMONTE s.c.p.a.minorGTM or Marketing Partner · 1 October 2025Italian trade facilitation organization that partnered with Rigenera HBW for participation in Medical Japan Tokyo 2025, one of Asia's most important trade fairs for the medical and healthcare industry.
• e-ribbingminorOthers · 1 January 2022HBW Group collaborated with e-ribbing to support the 'RIBBING FOR ARCTIC' mission, sailing across the Arctic Circle to raise awareness about climate change, provide medical support to remote Inuit settlements in Greenland, and document environmental conditions.
• NATO Science for Peace and Security (SPS)strategicStrategic or Co-development Partner · 1 January 2015HBW is part of RAWINTS project for Rapid Wound Healing by using Novel, Needle Free Delivery of Bioactive Micro-Graft Particles, financed by NATO Science for Peace and Security. Multi-year research project developing innovative solutions for military and civilian emergencies.
• European Space Agency (ESA)strategicStrategic or Co-development PartnerHBW Group is carrying out a project in collaboration with ESA to promote tissue repair and regeneration in space. Recent studies have shown that Rigenera® technology can promote tissue repair under microgravity conditions, opening new frontiers for medicine in space. This research is crucial for long-duration space missions where access to medical facilities is limited.
• Regenera ActivacoreChannel Partner/ Reseller/ DistributorCollaboration began in 2014 for Italian and Spanish market for hair line products. Regenera Activa manages worldwide distribution of Rigenera® Dermatology, Aesthetic Medicine and Pain Management & Sport Medicine lines.
• SHRO Italia Foundation ETSminorStrategic or Co-development PartnerOrganized the 'Biotech Network: A Meeting Between Research, Industry, and the Local Community' event at PTP – Polo Tecnologico Piemontese, bringing together key stakeholders from the biotech sector to discuss advances in regenerative medicine and collaboration opportunities.

Scale indicators11 records

Recent moves13 records

Expansion highlights7 records

Direct peers

• Organogenesis: US-listed regenerative medicine company focused on wound care and surgical biologics. Directly comparable to Rigenera's Woundigen line as both target chronic wound healing with autologous/biological grafts.
• MiMedx Group: US-listed company specializing in regenerative wound healing and surgical recovery using placental tissue allografts. Comparable to Rigenera in wound healing indication and physician-channel GTM.
• Geistlich Pharma: Swiss private company and global leader in dental bone and tissue regeneration (Bio-Oss, Bio-Gide). Most direct peer to Rigenera's StrongBone SB dental/OMF bone regeneration line.
• LifeNet Health: US non-profit tissue banking and regenerative medicine company with allograft-based wound, dental and orthopedic offerings. Comparable product breadth and physician-channel distribution to Rigenera.
• Lipogems International: Italian-headquartered company offering an autologous adipose-tissue micrografting system. Closest head-to-head peer to Rigenera — same country of origin, same autologous micrografting paradigm, overlapping aesthetic and orthopedic indications.

Broad incumbents

• Arthrex: Privately held global leader in sports medicine and orthobiologics. Directly competes with the Mytocel MSK line and has vastly deeper US orthopedic sales coverage.
• Coloplast: Danish-listed company with a leading wound care and ostomy franchise. Competes with Rigenera's wound healing portfolio with established hospital-channel relationships worldwide.
• Integra LifeSciences: Public regenerative and specialty surgical device company with wound care, neurosurgical and orthopedic regenerative offerings. Comparable in clinical breadth and consumable-driven model.
• Conmed: US-listed broad-line surgical and sports medicine device company with a regenerative biologics portfolio. Overlaps with Rigenera on the orthopedic/sports medicine side and on consumable-driven economics.
• Smith+Nephew: Global medical device incumbent with large advanced wound management, orthopedics and sports medicine portfolios. Competes with Rigenera across multiple verticals but at vastly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rigenera